The Entrance in Foreign Markets in the Field of Biotechnology and the Consideration of Socio-Cultural Particularities The Biotechnology Company MediGene and the People’s Republic of China
-
- Taschenbuch
- eBook ausgewählt
-
Form:Einzelkauf Download
-
Sprache:Englisch
15,99 €
inkl. gesetzl. MwSt.Beschreibung
Produktdetails
Format
ePUB
Kopierschutz
Nein
Family Sharing
Nein
Text-to-Speech
Ja
Erscheinungsdatum
07.04.2010
Verlag
GRINSeitenzahl
21 (Printausgabe)
Dateigröße
481 KB
Auflage
1. Auflage
Sprache
Englisch
EAN
9783640587117
Seminar paper from the year 2010 in the subject Business economics - Business Management, Corporate Governance, grade: "noch nicht bekanntgegeben", Baden-Wuerttemberg Cooperative State University (DHBW), language: English, abstract: For many years now China represents one of the most popular target markets of the internationalisation of enterprises. The speed of economic development and social changes of China during the last years is indeed enormous and far above average.
Today China is already the second largest economic nation and for many years receives the highest foreign investments worldwide. In 2002 China became Germany's biggest Asian trading partner taking the leadership over from Japan. Additionally 2012 shall be the German-Chinese cultural year.
A comparable rapid change and development can be seen in the field of biotechnology. Over the last few years biotechnology became more and more important, popular and underwent a tremendous boom.
Pharmaceutical industry is a sunrise industry, especially the biopharmaceuticals, which just starts its large-scale industrialization process. Many large biotech and pharmaceutical companies are strengthening their presence worldwide and have already entered the Chinese market - Roche, Novartis, GlaxoSmithKline and Pfizer, to name but a few. Among these as well BASF operates a joint venture together with the Chinese enterprise Sinopec for the production of high-quality chemical products and polymers.
This seminar paper evaluates possible market entry strategies for the small and medium enterprise MediGene AG into China taking account of socio-cultural particularities.
In the second chapter this seminar paper gives an insight into the characteristics of the Chinese culture and the biotechnological market in the People's Republic of China.
The subsequent third chapter contains information about the products and today's internationalisation of MediGene.
The fourth chapter is addressed to the different market entry strategies into China, which MediGene could choose.
Finally, the seminar paper comes out with a conclusion and recommendation for MediGene considering the won findings.
Today China is already the second largest economic nation and for many years receives the highest foreign investments worldwide. In 2002 China became Germany's biggest Asian trading partner taking the leadership over from Japan. Additionally 2012 shall be the German-Chinese cultural year.
A comparable rapid change and development can be seen in the field of biotechnology. Over the last few years biotechnology became more and more important, popular and underwent a tremendous boom.
Pharmaceutical industry is a sunrise industry, especially the biopharmaceuticals, which just starts its large-scale industrialization process. Many large biotech and pharmaceutical companies are strengthening their presence worldwide and have already entered the Chinese market - Roche, Novartis, GlaxoSmithKline and Pfizer, to name but a few. Among these as well BASF operates a joint venture together with the Chinese enterprise Sinopec for the production of high-quality chemical products and polymers.
This seminar paper evaluates possible market entry strategies for the small and medium enterprise MediGene AG into China taking account of socio-cultural particularities.
In the second chapter this seminar paper gives an insight into the characteristics of the Chinese culture and the biotechnological market in the People's Republic of China.
The subsequent third chapter contains information about the products and today's internationalisation of MediGene.
The fourth chapter is addressed to the different market entry strategies into China, which MediGene could choose.
Finally, the seminar paper comes out with a conclusion and recommendation for MediGene considering the won findings.
Noch keine Bewertungen vorhanden
Verfassen Sie die erste Bewertung zu diesem Artikel
Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.
Kurze Frage zu unserer Seite
Vielen Dank für Ihr Feedback
Wir nutzen Ihr Feedback, um unsere Produktseiten zu verbessern. Bitte haben Sie Verständnis, dass wir Ihnen keine Rückmeldung geben können. Falls Sie Kontakt mit uns aufnehmen möchten, können Sie sich aber gerne an unseren Kund*innenservice wenden.
zum Kundenservice